Atogepant and rimegepant for prophylaxis of migraine

Published on 04 Jun 2025
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended the following medications for inclusion on the MOH List of Subsidised Drugs, due to their uncertain comparative clinical effectiveness and substantially higher prices versus subsidised alternatives:

• Atogepant for prophylaxis of chronic migraine; and

• Atogepant or rimegepant for prophylaxis of episodic migraine.

Atogepant and rimegepant for prophylaxis of migraine [PDF, 674 KB]

PES_Atogepant and rimegepant for preventing migraine (Published 4 Jun 2025) [PDF, 77 KB]